Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANAB 
AnaptysBio Inc (ANAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: ANAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $42.55
1 Year Target Price $42.55
| 7 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 31.96% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 769.77M USD | Price to earnings Ratio - | 1Y Target Price 42.55 |
Price to earnings Ratio - | 1Y Target Price 42.55 | ||
Volume (30-day avg) 12 | Beta -0.27 | 52 Weeks Range 12.21 - 41.31 | Updated Date 07/12/2025 |
52 Weeks Range 12.21 - 41.31 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.76 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -125.7% | Operating Margin (TTM) -99.17% |
Management Effectiveness
Return on Assets (TTM) -15.14% | Return on Equity (TTM) -343.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 445407995 | Price to Sales(TTM) 6.88 |
Enterprise Value 445407995 | Price to Sales(TTM) 6.88 | ||
Enterprise Value to Revenue 3.98 | Enterprise Value to EBITDA -1.3 | Shares Outstanding 29380500 | Shares Floating 17605381 |
Shares Outstanding 29380500 | Shares Floating 17605381 | ||
Percent Insiders 5.1 | Percent Institutions 134.2 |
Upturn AI SWOT
AnaptysBio Inc
Company Overview
History and Background
AnaptysBio, Inc., founded in 2005, is a biotechnology company focused on developing novel antibody therapeutics. They utilize their proprietary antibody discovery technology to create potential first-in-class or best-in-class antibody product candidates.
Core Business Areas
- Therapeutic Antibody Development: Focuses on the discovery and development of therapeutic antibodies for various diseases, primarily in inflammation, oncology, and dermatology.
- Antibody Discovery Platform: Proprietary technology platform used to generate novel antibodies with desired properties.
Leadership and Structure
The company is led by a management team with expertise in antibody engineering, drug development, and commercialization. The organizational structure is typical of a biotech company, with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- Imsidolimab: An anti-IL-36R antibody being developed for various IL-36-mediated inflammatory diseases, including generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP). While specific market share is not publicly available yet, if approved, Imsidolimab aims to compete with existing and emerging therapies for these conditions. Competitors include Boehringer Ingelheim (spevigo) and other companies developing IL-17 or TNF inhibitors for skin conditions.
- Roxadustat: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). AnaptysBio is eligible to receive milestone payments based on the global sales of Roxadustat by GSK. The drug has already received marketing authorisations in countries including China, Japan, Europe and the UK for the treatment of anaemia associated with chronic kidney disease (CKD) in adult patients.Competitors include epoetin alfa and darbepoetin alfa, injectable erythropoiesis-stimulating agents.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long development timelines, and a high degree of risk. The antibody therapeutics market is growing rapidly due to increasing prevalence of chronic diseases and advancements in antibody engineering technologies.
Positioning
AnaptysBio aims to be a leader in developing novel antibody therapeutics for inflammatory and oncologic diseases by leveraging its antibody discovery platform. Their competitive advantage lies in their ability to generate antibodies with unique properties and their focus on unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for antibody therapeutics targeting inflammatory diseases and oncology is substantial, estimated in the tens of billions of dollars. AnaptysBio is positioned to capture a portion of this market with its pipeline of antibody product candidates. Exact TAM depends on specific indications targeted and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery platform
- Experienced management team
- Pipeline of novel antibody product candidates
- Partnerships with leading pharmaceutical companies
Weaknesses
- Dependence on clinical trial success
- High research and development costs
- Limited commercialization infrastructure
- Competition from larger pharmaceutical companies
Opportunities
- Expansion of pipeline into new therapeutic areas
- Strategic partnerships and collaborations
- Successful clinical trial results and regulatory approvals
- Out-licensing or sale of antibody product candidates
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
- Patent challenges
- Economic downturn affecting research funding
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- BMY
- GSK
Competitive Landscape
AnaptysBio faces competition from established pharmaceutical companies with greater resources and experience. Their advantage lies in their proprietary antibody discovery platform and their focus on innovative therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of antibody product candidates through clinical trials and the formation of strategic partnerships. Significant milestones such as positive clinical trial results and regulatory approvals have had a positive impact on the company's growth.
Future Projections: Future growth is dependent on the successful development and commercialization of antibody product candidates. Analyst estimates vary depending on the perceived probability of success for key clinical programs.
Recent Initiatives: Recent initiatives include advancing Imsidolimab through Phase 3 clinical trials, expanding the pipeline into new therapeutic areas, and exploring new partnership opportunities.
Summary
AnaptysBio is a clinical-stage biotechnology company with a proprietary antibody discovery platform. Its strength lies in its innovative technology and pipeline, however, it faces challenges in funding and competition. Success hinges on positive clinical trial outcomes and strategic partnerships. Investors should monitor clinical progress and financial stability closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- AnaptysBio Inc. Investor Relations
- SEC Filings
- Industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and due diligence. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AnaptysBio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2017-01-26 | President, CEO & Director Mr. Daniel R. Faga | ||
Sector Healthcare | Industry Biotechnology | Full time employees 136 | Website https://www.anaptysbio.com |
Full time employees 136 | Website https://www.anaptysbio.com | ||
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.